| Novel multi-target-directed ligands for Alzheimer's disease: combining cholinesterase inhibitors and 5-HT6 receptor antagonists. Design, synthesis and biological evaluation A Więckowska, M Kołaczkowski, A Bucki, J Godyń, M Marcinkowska, ... European Journal of Medicinal Chemistry 124, 63-81, 2016 | 84 | 2016 |
| Ligand-Optimized Homology Models of D1 and D2 Dopamine Receptors: Application for Virtual Screening M Kołaczkowski, A Bucki, M Feder, M Pawłowski Journal of chemical information and modeling 53 (3), 638-648, 2013 | 73 | 2013 |
| Novel Arylsulfonamide Derivatives with 5-HT6/5-HT7 Receptor Antagonism Targeting Behavioral and Psychological Symptoms of Dementia M Kołaczkowski, M Marcinkowska, A Bucki, M Pawłowski, K Mitka, ... Journal of medicinal chemistry 57 (11), 4543-4557, 2014 | 68 | 2014 |
| Metabolic carbonyl reduction of anthracyclines—role in cardiotoxicity and cancer resistance. Reducing enzymes as putative targets for novel cardioprotective and … K Piska, P Koczurkiewicz, A Bucki, K Wójcik-Pszczoła, M Kołaczkowski, ... Investigational new drugs 35, 375-385, 2017 | 64 | 2017 |
| Novel multitarget-directed ligands aiming at symptoms and causes of Alzheimer’s disease A Wieckowska, T Wichur, J Godyń, A Bucki, M Marcinkowska, A Siwek, ... ACS chemical neuroscience 9 (5), 1195-1214, 2018 | 54 | 2018 |
| Novel butanehydrazide derivatives of purine-2, 6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: design, synthesis and biological evaluation G Chłoń-Rzepa, A Jankowska, M Ślusarczyk, A Świerczek, K Pociecha, ... European journal of medicinal chemistry 146, 381-394, 2018 | 44 | 2018 |
| Phosphodiesterase 10 inhibitors-novel perspectives for psychiatric and neurodegenerative drug discovery A Zagórska, A Partyka, A Bucki, A Gawalskax, A Czopek, M Pawlowski Current medicinal chemistry 25 (29), 3455-3481, 2018 | 42 | 2018 |
| Idalopirdine – a small molecule antagonist of 5-HT6 with therapeutic potential against obesity M Dudek, M Marcinkowska, A Bucki, A Olczyk, M Kołaczkowski Metabolic Brain Disease 30, 1487-1494, 2015 | 39 | 2015 |
| Antidepressant-and anxiolytic-like activity of 7-phenylpiperazinylalkyl-1, 3-dimethyl-purine-2, 6-dione derivatives with diversified 5-HT1A receptor functional profile A Partyka, G Chłoń-Rzepa, A Wasik, M Jastrzębska-Więsek, A Bucki, ... Bioorganic & medicinal chemistry 23 (1), 212-221, 2015 | 38 | 2015 |
| Novel 5-HT6 receptor antagonists/D2 receptor partial agonists targeting behavioral and psychological symptoms of dementia M Kołaczkowski, M Marcinkowska, A Bucki, J Śniecikowska, M Pawłowski, ... European Journal of Medicinal Chemistry 92, 221-235, 2015 | 36 | 2015 |
| Idalopirdine, a selective 5-HT6 receptor antagonist, reduces food intake and body weight in a model of excessive eating M Kotańska, K Lustyk, A Bucki, M Marcinkowska, J Śniecikowska, ... Metabolic brain disease 33, 733-740, 2018 | 35 | 2018 |
| Design, synthesis, and biological evaluation of fluorinated imidazo [1, 2-a] pyridine derivatives with potential antipsychotic activity M Marcinkowska, M Kołaczkowski, K Kamiński, A Bucki, M Pawłowski, ... European Journal of Medicinal Chemistry 124, 456-467, 2016 | 35 | 2016 |
| Novel spirohydantoin derivative as a potent multireceptor-active antipsychotic and antidepressant agent A Czopek, M Kołaczkowski, A Bucki, H Byrtus, M Pawłowski, G Kazek, ... Bioorganic & Medicinal Chemistry 23 (13), 3436-3447, 2015 | 35 | 2015 |
| Synergistic anticancer activity of doxorubicin and piperlongumine on DU-145 prostate cancer cells–the involvement of carbonyl reductase 1 inhibition K Piska, P Koczurkiewicz, D Wnuk, E Karnas, A Bucki, K Wójcik-Pszczoła, ... Chemico-Biological Interactions 300, 40-48, 2019 | 34 | 2019 |
| Evaluation of 1‐arylpiperazine derivative of hydroxybenzamides as 5‐HT1A and 5‐HT7 serotonin receptor ligands: An experimental and molecular modeling … P Kowalski, J Jaśkowska, AJ Bojarski, B Duszyńska, A Bucki, ... Journal of Heterocyclic Chemistry 48 (1), 192-198, 2011 | 33 | 2011 |
| Novel amide derivatives of 1, 3-dimethyl-2, 6-dioxopurin-7-yl-alkylcarboxylic acids as multifunctional TRPA1 antagonists and PDE4/7 inhibitors: a new approach for the treatment … G Chłoń-Rzepa, M Ślusarczyk, A Jankowska, A Gawalska, A Bucki, ... European Journal of Medicinal Chemistry 158, 517-533, 2018 | 32 | 2018 |
| Structure–activity relationships and molecular studies of novel arylpiperazinylalkyl purine-2, 4-diones and purine-2, 4, 8-triones with antidepressant and anxiolytic-like activity A Zagórska, M Kołaczkowski, A Bucki, A Siwek, G Kazek, G Satała, ... European Journal of Medicinal Chemistry 97, 142-154, 2015 | 31 | 2015 |
| Advances in discovery of PDE10A inhibitors for CNS-related disorders. Part 1: overview of the chemical and biological research A Jankowska, A Świerczek, E Wyska, A Gawalska, A Bucki, M Pawłowski, ... Current Drug Targets 20 (1), 122-143, 2019 | 28 | 2019 |
| Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1H-indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity A Bucki, M Marcinkowska, J Sniecikowska, K Wieckowski, M Pawłowski, ... Journal of Medicinal Chemistry 60 (17), 7483-7501, 2017 | 28 | 2017 |
| Novel aryloxyethyl derivatives of 1-(1-benzoylpiperidin-4-yl) methanamine as the extracellular regulated kinases 1/2 (ERK1/2) phosphorylation-preferring serotonin 5-HT1A … J Sniecikowska, M Gluch-Lutwin, A Bucki, A Wieckowska, A Siwek, ... Journal of Medicinal Chemistry 62 (5), 2750-2771, 2019 | 26 | 2019 |
